Merck Sharp + Dohme Corp.

Ambrx, Inc.

Rakuten Medical, Inc.

Ambryx, Inc.

Anthony Manibusan

Nick Knudsen

Robert M Garbaccio

Dennis P Gately

Ying Sun

Elisabetta Bianchi

Linda Liang

Jeffrey Curtis Kern

Federica Orvieto

Wolfgang Seghezzi

Philip E Brandish

Jianing Wang

Paul E Carrington

Grigori Ermakov

Andrew Beck

Sanjiv Shah

Zahra Shahrokh

Dennis Zaller

Provided are compositions containing a conjugate containing a phthalocyanine dye, including compositions containing stabilizing agents, such as non-ionic surfactants and/or protectants. In some aspects, the compositions result reduced aggregation of the conjugate due to agitation, temperature exposure, and/or pH. Also provided are articles of manufacture containing the compositions containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

Phthalocyanine dye conjugate compositions

Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors

Antibody drug conjugates (ADCs) comprising an antibody conjugated to an anti-inflammatory therapeutic agent via a phosphate-based linker with tunable extracellular and intracellular stability are described.

Antibody drug conjugate for anti-inflammatory applications

Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).

Phosphate based linkers for intracellular delivery of drug conjugates

Growing community of inventors

San Diego, CA, United States of America

Anthony Manibusan